249 related articles for article (PubMed ID: 31084193)
21. Gamma distribution model of diffusion MRI for evaluating the isocitrate dehydrogenase mutation status of glioblastomas.
Takase H; Togao O; Kikuchi K; Hata N; Hatae R; Chikui T; Tokumori K; Kami Y; Kuga D; Sangatsuda Y; Mizoguchi M; Hiwatashi A; Ishigami K
Br J Radiol; 2022 May; 95(1133):20210392. PubMed ID: 35138915
[TBL] [Abstract][Full Text] [Related]
22. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
[TBL] [Abstract][Full Text] [Related]
23. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.
Ozturk K; Soylu E; Cayci Z
Neuroradiology; 2021 Nov; 63(11):1801-1810. PubMed ID: 33738509
[TBL] [Abstract][Full Text] [Related]
24. Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.
Wen JB; Huang WY; Xu WX; Wu G; Geng DY; Yin B
J Comput Assist Tomogr; 2017; 41(6):904-909. PubMed ID: 28708728
[TBL] [Abstract][Full Text] [Related]
25. Sequential implementation of DSC-MR perfusion and dynamic [
Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
[TBL] [Abstract][Full Text] [Related]
26. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
27. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
28. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.
Siakallis L; Topriceanu CC; Panovska-Griffiths J; Bisdas S
Neuroradiology; 2023 Jul; 65(7):1111-1126. PubMed ID: 37173578
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings.
Gezer B; Mutlukan A; Sahinoglu M; Karabagli PN; Koktekir E; Karabagli H
Turk Neurosurg; 2020; 30(3):422-427. PubMed ID: 32091123
[TBL] [Abstract][Full Text] [Related]
30. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
[TBL] [Abstract][Full Text] [Related]
31. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
32. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
33. Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Lo CM; Weng RC; Cheng SJ; Wang HJ; Hsieh KL
Medicine (Baltimore); 2020 Feb; 99(8):e19123. PubMed ID: 32080088
[TBL] [Abstract][Full Text] [Related]
34. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
35. Gyriform infiltration as imaging biomarker for molecular glioblastomas.
Mesny E; Barritault M; Izquierdo C; Poncet D; d'Hombres A; Guyotat J; Jouanneau E; Ameli R; Honnorat J; Meyronet D; Ducray F
J Neurooncol; 2022 May; 157(3):511-521. PubMed ID: 35364762
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive assessment of heterogeneity of gliomas using diffusion and perfusion MRI: correlation with spatially co-registered PET.
Zhang Y; Lin Y; Xing Z; Yao S; Cao D; Miao WB
Acta Radiol; 2022 May; 63(5):664-671. PubMed ID: 33858207
[TBL] [Abstract][Full Text] [Related]
37. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
[TBL] [Abstract][Full Text] [Related]
38. Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.
Uetani H; Azuma M; Khant ZA; Watanabe Y; Kudo K; Kadota Y; Yokogami K; Takeshima H; Kuroda JI; Shinojima N; Hamasaki T; Mukasa A; Hirai T
J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):659-665. PubMed ID: 36877775
[TBL] [Abstract][Full Text] [Related]
39. Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
Park JE; Eun D; Kim HS; Lee DH; Jang RW; Kim N
Sci Rep; 2021 May; 11(1):9912. PubMed ID: 33972663
[TBL] [Abstract][Full Text] [Related]
40. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]